Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 19

  • 956 clinical trials
  • 393 recruiting
  • 345 conditions
  • 28 countries

Conditions in this area

345 conditions with trials, the busiest first

Breast cancer168Prostate cancer101Ovarian cancer91Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer41Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer18Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+321

Clinical trials in Reproductive system and breast disorders

956 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

956 clinical trials

Breast cancer metastatic+3

Recruiting

Study on the Impact of Exercise and Atorvastatin on Advanced Breast, Ovarian, Prostate, and Kidney Cancer Patients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Pirkanmaan hyvinvointialue

Bacterial prostatitis

Recruiting

Study on the Effectiveness of Fosfomycin, Cefixime, and Ciprofloxacin in Treating Acute Bacterial Prostatitis in Adult Men

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cefixime
  • Sponsor:Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca

Ovarian epithelial cancer

Recruiting

Study on Letrozole Maintenance Therapy for Patients with Epithelial Ovarian Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Swiss GO Trial Group

Uveitis+1

Recruiting

Study on the Effectiveness and Safety of Tocilizumab and Adalimumab for Patients with Severe Uveitis in Behçet’s Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Neuroendocrine tumour+6

Recruiting

Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Pyruvic Acid
  • Sponsor:Region Hovedstaden

Cervical dysplasia

Recruiting

Study on Improving Cervical Dysplasia Diagnosis in Postmenopausal Women Using Estradiol

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Estradiol
  • Sponsor:Region Midtjylland

Lymphangiosarcoma+34

Recruiting

Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ttf-Ngr
  • Sponsor:Universitaet Muenster

Endometrial cancer

Recruiting

Study of Pembrolizumab for Patients with Mismatch Repair Deficient Uterine Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Universitair Medisch Centrum Groningen

Breast cancer

Recruiting

Study on Personalized Treatment for Hormone Receptor Positive HER2 Negative Breast Cancer Using Capivasertib, Letrozole, and Bevacizumab for Eligible Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Oslo University Hospital HF

Breast cancer

Recruiting

Study on Pravastatin for Patients with Severe Radio-Induced Breast Fibrosis After Breast Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pravastatin Sodium
  • Sponsor:Institut Regional Du Cancer De Montpellier

Breast cancer

Recruiting

Study on Breast Cancer Treatment with Carboplatin for Patients in Neoadjuvant and Metastatic Stages

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Oslo University Hospital HF

Ovarian cancer

Recruiting

Title: Study of 5-Aminolevulinic Acid for detecting tumor tissue during surgery in patients with ovarian cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aminolevulinic Acid Hydrochloride
  • Sponsor:Rheinische Friedrich-Wilhelms-Universitaet Bonn

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab77 clinical trialsLetrozole73 clinical trialsFulvestrant58 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane46 clinical trialsAnastrozole44 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.